An Open-label, Dose-escalation Phase I/Ib Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of AsiDNA, a DNA Repair Inhibitor Administered Intravenously, as Single Agent and to Assess the Safety and the Efficacy of AsiDNA in Combination With Carboplatin With or Without Paclitaxel, in Patients With Advanced Solid Tumors
Latest Information Update: 18 Dec 2023
At a glance
- Drugs Etidaligide (Primary)
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions
- Acronyms DRIIV; DRIIV-1
- Sponsors Onxeo SA; Valerio Therapeutics
- 18 Mar 2022 Status changed from active, no longer recruiting to completed.
- 21 May 2021 Planned End Date changed from 30 Sep 2020 to 28 May 2022.
- 21 May 2021 Status changed from completed to active, no longer recruiting.